436 related articles for article (PubMed ID: 17218256)
1. Increased myeloid cell responses to M-CSF and RANKL cause bone loss and inflammation in SH3BP2 "cherubism" mice.
Ueki Y; Lin CY; Senoo M; Ebihara T; Agata N; Onji M; Saheki Y; Kawai T; Mukherjee PM; Reichenberger E; Olsen BR
Cell; 2007 Jan; 128(1):71-83. PubMed ID: 17218256
[TBL] [Abstract][Full Text] [Related]
2. SH3BP2 cherubism mutation potentiates TNF-α-induced osteoclastogenesis via NFATc1 and TNF-α-mediated inflammatory bone loss.
Mukai T; Ishida S; Ishikawa R; Yoshitaka T; Kittaka M; Gallant R; Lin YL; Rottapel R; Brotto M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014 Dec; 29(12):2618-35. PubMed ID: 24916406
[TBL] [Abstract][Full Text] [Related]
3. Jawing about TNF: new hope for cherubism.
Novack DV; Faccio R
Cell; 2007 Jan; 128(1):15-7. PubMed ID: 17218248
[TBL] [Abstract][Full Text] [Related]
4. Cherubism Mice Also Deficient in c-Fos Exhibit Inflammatory Bone Destruction Executed by Macrophages That Express MMP14 Despite the Absence of TRAP+ Osteoclasts.
Kittaka M; Mayahara K; Mukai T; Yoshimoto T; Yoshitaka T; Gorski JP; Ueki Y
J Bone Miner Res; 2018 Jan; 33(1):167-181. PubMed ID: 28914985
[TBL] [Abstract][Full Text] [Related]
5. Bone marrow transplantation improves autoinflammation and inflammatory bone loss in SH3BP2 knock-in cherubism mice.
Yoshitaka T; Kittaka M; Ishida S; Mizuno N; Mukai T; Ueki Y
Bone; 2015 Feb; 71():201-9. PubMed ID: 25445458
[TBL] [Abstract][Full Text] [Related]
6. SH3BP2 gain-of-function mutation exacerbates inflammation and bone loss in a murine collagen-induced arthritis model.
Mukai T; Gallant R; Ishida S; Yoshitaka T; Kittaka M; Nishida K; Fox DA; Morita Y; Ueki Y
PLoS One; 2014; 9(8):e105518. PubMed ID: 25144740
[TBL] [Abstract][Full Text] [Related]
7. Rescue of a cherubism bone marrow stromal culture phenotype by reducing TGFβ signaling.
Liu Y; Sharma T; Chen IP; Reichenberger E; Ueki Y; Arif Y; Parisi D; Maye P
Bone; 2018 Jun; 111():28-35. PubMed ID: 29530719
[TBL] [Abstract][Full Text] [Related]
8. Second-Generation SYK Inhibitor Entospletinib Ameliorates Fully Established Inflammation and Bone Destruction in the Cherubism Mouse Model.
Yoshimoto T; Hayashi T; Kondo T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2018 Aug; 33(8):1513-1519. PubMed ID: 29669173
[TBL] [Abstract][Full Text] [Related]
9. Enhanced TLR-MYD88 signaling stimulates autoinflammation in SH3BP2 cherubism mice and defines the etiology of cherubism.
Yoshitaka T; Mukai T; Kittaka M; Alford LM; Masrani S; Ishida S; Yamaguchi K; Yamada M; Mizuno N; Olsen BR; Reichenberger EJ; Ueki Y
Cell Rep; 2014 Sep; 8(6):1752-1766. PubMed ID: 25220465
[TBL] [Abstract][Full Text] [Related]
10. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
11. Alveolar Bone Protection by Targeting the SH3BP2-SYK Axis in Osteoclasts.
Kittaka M; Yoshimoto T; Schlosser C; Rottapel R; Kajiya M; Kurihara H; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2020 Feb; 35(2):382-395. PubMed ID: 31613396
[TBL] [Abstract][Full Text] [Related]
12. Etanercept administration to neonatal SH3BP2 knock-in cherubism mice prevents TNF-α-induced inflammation and bone loss.
Yoshitaka T; Ishida S; Mukai T; Kittaka M; Reichenberger EJ; Ueki Y
J Bone Miner Res; 2014; 29(5):1170-82. PubMed ID: 24978678
[TBL] [Abstract][Full Text] [Related]
13. High dose M-CSF partially rescues the Dap12-/- osteoclast phenotype.
Faccio R; Zou W; Colaianni G; Teitelbaum SL; Ross FP
J Cell Biochem; 2003 Dec; 90(5):871-83. PubMed ID: 14624447
[TBL] [Abstract][Full Text] [Related]
14. Enhancement of B-cell receptor signaling by a point mutation of adaptor protein 3BP2 identified in human inherited disease cherubism.
Ogi K; Nakashima K; Chihara K; Takeuchi K; Horiguchi T; Fujieda S; Sada K
Genes Cells; 2011 Sep; 16(9):951-60. PubMed ID: 21794028
[TBL] [Abstract][Full Text] [Related]
15. [Molecular and Cellular Pathogenesis of Cherubism].
Ueki Y
Clin Calcium; 2016 Jun; 26(6):918-26. PubMed ID: 27230848
[TBL] [Abstract][Full Text] [Related]
16. Adaptor protein 3BP2 and cherubism.
Hatani T; Sada K
Curr Med Chem; 2008; 15(6):549-54. PubMed ID: 18336269
[TBL] [Abstract][Full Text] [Related]
17. Pro416Arg cherubism mutation in Sh3bp2 knock-in mice affects osteoblasts and alters bone mineral and matrix properties.
Wang CJ; Chen IP; Koczon-Jaremko B; Boskey AL; Ueki Y; Kuhn L; Reichenberger EJ
Bone; 2010 May; 46(5):1306-15. PubMed ID: 20117257
[TBL] [Abstract][Full Text] [Related]
18. SH3BP2 mutations potentiate osteoclastogenesis via PLCγ.
Lietman SA; Yin L; Levine MA
J Orthop Res; 2010 Nov; 28(11):1425-30. PubMed ID: 20872577
[TBL] [Abstract][Full Text] [Related]
19. Loss of SH3 domain-binding protein 2 function suppresses bone destruction in tumor necrosis factor-driven and collagen-induced arthritis in mice.
Mukai T; Gallant R; Ishida S; Kittaka M; Yoshitaka T; Fox DA; Morita Y; Nishida K; Rottapel R; Ueki Y
Arthritis Rheumatol; 2015 Mar; 67(3):656-67. PubMed ID: 25470448
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor necrosis factor treatment in cherubism--clinical, radiological and histological findings in two children.
Hero M; Suomalainen A; Hagström J; Stoor P; Kontio R; Alapulli H; Arte S; Toiviainen-Salo S; Lahdenne P; Mäkitie O
Bone; 2013 Jan; 52(1):347-53. PubMed ID: 23069372
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
